- Home
- MMV vs APRE Comparison
MMV vs APRE Comparison
Compare MMV & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMV
- APRE
- Stock Information
- Founded
- MMV 2015
- APRE 2006
- Country
- MMV China
- APRE United States
- Employees
- MMV N/A
- APRE N/A
- Industry
- MMV Blank Checks
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MMV Finance
- APRE Health Care
- Exchange
- MMV Nasdaq
- APRE Nasdaq
- Market Cap
- MMV 18.8M
- APRE 20.2M
- IPO Year
- MMV N/A
- APRE 2019
- Fundamental
- Price
- MMV $0.49
- APRE $3.24
- Analyst Decision
- MMV
- APRE Strong Buy
- Analyst Count
- MMV 0
- APRE 2
- Target Price
- MMV N/A
- APRE $15.50
- AVG Volume (30 Days)
- MMV 149.6K
- APRE 5.9K
- Earning Date
- MMV 01-01-0001
- APRE 11-07-2024
- Dividend Yield
- MMV N/A
- APRE N/A
- EPS Growth
- MMV N/A
- APRE N/A
- EPS
- MMV N/A
- APRE N/A
- Revenue
- MMV $9,008,244.00
- APRE $1,275,686.00
- Revenue This Year
- MMV N/A
- APRE $96.15
- Revenue Next Year
- MMV N/A
- APRE N/A
- P/E Ratio
- MMV N/A
- APRE N/A
- Revenue Growth
- MMV N/A
- APRE 410.91
- 52 Week Low
- MMV $0.41
- APRE $2.99
- 52 Week High
- MMV $2.05
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- MMV 38.30
- APRE 38.29
- Support Level
- MMV $0.46
- APRE $3.03
- Resistance Level
- MMV $0.54
- APRE $3.50
- Average True Range (ATR)
- MMV 0.05
- APRE 0.20
- MACD
- MMV -0.00
- APRE -0.02
- Stochastic Oscillator
- MMV 31.94
- APRE 21.31
About MMV MultiMetaVerse Holdings Limited
MultiMetaVerse Holdings Ltd is an animation and entertainment company. It is devoted to establishing an open community for its global users comprised of animation viewers, game players, and content creators and to providing high-quality and immersive entertainment experiences by way of original content, user-generated content, and professional user-generated content.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).